Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

4-hexylresorcinol exerts antitumor effects via suppression of calcium oscillation and its antitumor effects are inhibited by calcium channel blockers.

Kim SG, Choi JY.

Oncol Rep. 2013 May;29(5):1835-40. doi: 10.3892/or.2013.2292. Epub 2013 Feb 19.

PMID:
23427012
2.

Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study.

Lee SW, Kim SG, Park YW, Kweon H, Kim JY, Rotaru H.

Tumour Biol. 2013 Jun;34(3):1595-603. doi: 10.1007/s13277-013-0690-6. Epub 2013 Feb 15.

PMID:
23412976
3.

4-hexylresorcinol stimulates the differentiation of SCC-9 cells through the suppression of E2F2, E2F3 and Sp3 expression and the promotion of Sp1 expression.

Kim SG, Kim AS, Jeong JH, Choi JY, Kweon H.

Oncol Rep. 2012 Aug;28(2):677-81. doi: 10.3892/or.2012.1845. Epub 2012 Jun 1.

PMID:
22664654
4.

Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.

Harada K, Supriatno, Yamamoto S, Kawaguchi S, Yoshida H, Sato M.

Anticancer Res. 2003 Mar-Apr;23(2B):1441-8.

PMID:
12820407
5.

Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma.

Liu PY, Sheu JJ, Lin PC, Lin CT, Liu YJ, Ho LI, Chang LF, Wu WC, Chen SR, Chen J, Harn YC, Lin SZ, Tsai CH, Chiou TW, Harn HJ.

Invest New Drugs. 2012 Feb;30(1):79-89. doi: 10.1007/s10637-010-9518-z. Epub 2010 Sep 1.

PMID:
20809206
6.

Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.

Okui T, Shimo T, Hassan NM, Fukazawa T, Kurio N, Takaoka M, Naomoto Y, Sasaki A.

Anticancer Res. 2011 Apr;31(4):1197-204.

PMID:
21508365
7.

1'-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations.

In LL, Arshad NM, Ibrahim H, Azmi MN, Awang K, Nagoor NH.

BMC Complement Altern Med. 2012 Oct 9;12:179. doi: 10.1186/1472-6882-12-179.

8.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
9.

Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.

Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M, Shintani S.

Int J Oncol. 2007 Jun;30(6):1469-76.

PMID:
17487368
10.

Heparin induces apoptosis through suppression of AKt in oral squamous cell carcinoma cells.

Ueda K, Inoue S, Zhang Y, Kutsuna T, Inoue S, Noto K, Arai N, Noguchi M.

Anticancer Res. 2009 Apr;29(4):1079-88.

11.

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.

Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y, Zheng D.

BMC Cancer. 2011 Feb 3;11:54. doi: 10.1186/1471-2407-11-54.

12.

The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.

Shin M, Matsuo K, Tada T, Fukushima H, Furuta H, Ozeki S, Kadowaki T, Yamamoto K, Okamoto M, Jimi E.

Carcinogenesis. 2011 Nov;32(11):1634-40. doi: 10.1093/carcin/bgr198. Epub 2011 Sep 1.

PMID:
21890459
13.
14.
15.

Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.

Ferdous T, Harada K, Kin T, Harada T, Ueyama Y.

Int J Oncol. 2013 Jul;43(1):271-9. doi: 10.3892/ijo.2013.1950. Epub 2013 May 20.

PMID:
23695365
16.

Cytotoxic activity of styrylchromones against human tumor cell lines.

Momoi K, Sugita Y, Ishihara M, Satoh K, Kikuchi H, Hashimoto K, Yokoe I, Nishikawa H, Fujisawa S, Sakagami H.

In Vivo. 2005 Jan-Feb;19(1):157-63.

17.

Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.

Cohen SM, Mukerji R, Samadi AK, Zhang X, Zhao H, Blagg BS, Cohen MS.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S483-90. doi: 10.1245/s10434-011-1971-1. Epub 2011 Aug 12. Erratum in: Ann Surg Oncol. 2012 May;19(5):1720. Zhang, Xuan [added].

PMID:
21837531
18.

[Antitumor effects of ring-closed and ring-opened hydroxycamptothecin on oral squamous carcinoma cell line Tca8113].

Wang AX, Li S, Ding XQ, Chen Y, Chen D.

Ai Zheng. 2005 Aug;24(8):970-4. Chinese.

PMID:
16086875
19.

2'-Hydroxycinnamaldehyde shows antitumor activity against oral cancer in vitro and in vivo in a rat tumor model.

Kim SA, Sung YK, Kwon BM, Yoon JH, Lee H, Ahn SG, Hong SH.

Anticancer Res. 2010 Feb;30(2):489-94.

PMID:
20332459
20.

Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.

Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.

Cancer Lett. 2010 Jun 1;292(1):54-63. doi: 10.1016/j.canlet.2009.11.004. Epub 2009 Dec 2.

PMID:
19959278

Supplemental Content

Support Center